AdLip: Use of Human Coach-supported Digital/AI Personal Health Assistant to Improve Adherence to Lipid-Lowering Medications: a Multi-centre Randomised Controlled Trial

Status: Recruiting
Location: See all (2) locations...
Intervention Type: Behavioral
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Investigators hypothesize that the use of a human coach-supported digital/AI personal health assistant (app) will improve adherence to cholesterol-lowering medications (statins with or without ezetimibe) among patients with hyperlipidaemia and suboptimal LDL-C control, when compared to standard care.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 21
Maximum Age: 84
Healthy Volunteers: t
View:

• Between 21 to 84 years old

• Prescribed statins with or without ezetimibe for hyperlipidaemia.

• Medication non-adherence as defined by the \"Extent to Non-adherence\" sub-scale of the DOSE Non-Adherence Measure), with a score \> 1 (range from 0-15)

• Singapore residents (citizens, permanent residents, or long-term pass holders).

• In possession of a smartphone or tablet with Android or iOS operating systems.

• Have internet access on their mobile devices.

Locations
Other Locations
Singapore
National Healthcare Group Polyclinics
RECRUITING
Singapore
National University Polyclinics
RECRUITING
Singapore
Contact Information
Primary
Doreen Su-Yin Tan, Pharm.D.
doreen.tan.sy@nus.edu.sg
66016471
Time Frame
Start Date: 2024-06-10
Estimated Completion Date: 2026-02-14
Participants
Target number of participants: 450
Treatments
No_intervention: Standard care
Receive usual standard of care for lipid management
Experimental: Standard care + Human Coach-supported Digital/AI Personal Health Assistant
The intervention group will receive personalised feedback through the digital mobile health app coupled with human coaching (i.e., support from a human coach-supported digital/AI personal health assistant) on top of usual clinical care for cholesterol management.
Related Therapeutic Areas
Sponsors
Leads: National University of Singapore
Collaborators: National University Polyclinics, Singapore, Nanyang Technological University, National Healthcare Group Polyclinics, Consortium for Clinical Research and Innovation, Singapore (CRIS), National University Heart Centre, Singapore

This content was sourced from clinicaltrials.gov